Fig. 3

Association of HBV-specific T cell reactivity with anti-virus therapy in CHB patients. A HBV-specific T cells (SFUs) in CHB patients with different treatments. B Specific T cells (SFUs) reactive to each HBV protein (HBsAg, HBpol, HBx, HBeAg) in different treatment groups. Untreated group, n = 15; NUCs monotherapy, n = 167; NUCs/IFN combination therapy, n = 21. C HBV-specific T cells (SFUs) after NUCs treatment in different durations of treatment. D HBV-specific T cells (SFUs) after different NUCs treatment in the same treatment duration. Medians (interquartile range) were presented and statistical analyses were performed using Kruskal–Wallis test (K–W) across multiple groups and Mann–Whitney test (M–W) between two groups